Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
Top Cited Papers
- 19 June 2008
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 358 (25) , 2698-2703
- https://doi.org/10.1056/nejmoa0800251
Abstract
We developed an in vitro method for isolating and expanding autologous CD4+ T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1. We infused these cells into a patient with refractory metastatic melanoma who had not undergone any previous conditioning or cytokine treatment. We show that the transferred CD4+ T cells mediated a durable clinical remission and led to endogenous responses against melanoma antigens other than NY-ESO-1.Keywords
This publication has 21 references indexed in Scilit:
- Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancerProceedings of the National Academy of Sciences, 2007
- Phase I Study of Adoptive T-Cell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients With Metastatic MelanomaJournal of Clinical Oncology, 2006
- Adoptive immunotherapy for cancer: building on successNature Reviews Immunology, 2006
- Transfection of RNA Encoding Tumor Antigens Following Maturation of Dendritic Cells Leads to Prolonged Presentation of Antigen and the Generation of High-Affinity Tumor-Reactive Cytotoxic T LymphocytesMolecular Therapy, 2004
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor LymphocytesScience, 2002
- Phase I Trial of Adoptive Immunotherapy With Cytolytic T Lymphocytes Immunized Against a Tyrosinase EpitopeJournal of Clinical Oncology, 2002
- Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor CellsPublished by Elsevier ,1991
- The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cellsJournal of Immunological Methods, 1990
- Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.The Journal of Experimental Medicine, 1985
- Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay.The Journal of Experimental Medicine, 1976